Skip to main content
      #EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating &

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      #EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating & diarrhoea) in scleroderma. How about impact on faecal incontinence symptoms? This improved throughout 20wks. Could be due improved stool consistency @RheumNow https://t.co/1t7d3M5S4Z
      Two large retrospective cohort studies presented by the team at Mayo Clinic, Rochester MN examine the burden of stroke, as well as overall and cause-specific mortality in people with RA (POS0591 and POS0592).
      #EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ika

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      #EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo
      PsA: one composite index that does it all

      cDAPSA + Investigator’s Global Assessment (IGA) of PSO
      Cohen’s kappa 0.72

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      PsA: one composite index that does it all cDAPSA + Investigator’s Global Assessment (IGA) of PSO Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA 88% sensitivity & specificity in DISCOVER-1 & 2 trial data #EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC
      🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer
      38 PSO patients w/ arthralgia
      Correlation PET/CT SUVmax, TJC

      Aurelie Najm AurelieRheumo

      3 months 2 weeks ago
      🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer 38 PSO patients w/ arthralgia Correlation PET/CT SUVmax, TJC & tender enthesis count 68Ga-FAPI-04 uptake = higher risk developing PsA 6mo Shows signs of inflammation before MSUS! #EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn
      Leflunomide for #PMR?

      ✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica

      V fast withdrawal of #

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      Leflunomide for #PMR? ✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica V fast withdrawal of #prednisone #LEF ~4 to 5 months #MTX 30 mos! ⬇️flares w LEF 😮 #EULAR2024 @RheumNow @eular_org @SebaUltraTrail https://t.co/2hk0yMH6gY
      🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry

      ➡️Cognitive symptoms si

      Mrinalini Dey DrMiniDey

      3 months 2 weeks ago
      🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry ➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs ➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL @RheumNow #EULAR2024
      This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB
      Does TCZ switch off GCA histopathologically?

      GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery bio

      David Liew drdavidliew

      3 months 2 weeks ago
      Does TCZ switch off GCA histopathologically? GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat) Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary #EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0
      RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. Al

      Dr. John Cush RheumNow

      3 months 2 weeks ago
      RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.
      Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seron

      Dr. John Cush RheumNow

      3 months 2 weeks ago
      Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T